Current practices for treatment of respiratory syncytial virus and other non-influenza respiratory viruses in high-risk patient populations: A survey of institutions in the Midwestern Respiratory Virus Collaborative

Transplant Infectious Disease

Volumn 18, Issue 2, 2016, Pages 210-215

  Beaird, O E ^a   Freifeld, A ^b   Ison, M G ^c   Lawrence, S J ^d   Theodoropoulos, N ^e   Clark, N M ^f   Razonable, R R ^g   Alangaden, G ^h   Miller, R ⁱ   Smith, J ^j   Young, J A H ^k   Hawkinson, D ^l   Pursell, K ^m   Kaul, Daniel R ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d WASHINGTON UNIVERSITY   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^g MAYO CLINIC   (United States)

^h HENRY FORD HEALTH SYSTEM   (United States)

ⁱ UNIVERSITY OF IOWA   (United States)

^j UNIVERSITY OF WISCONSIN MADISON   (United States)

^k UNIVERSITY OF MINNESOTA   (United States)

^l UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^m UNIVERSITY OF CHICAGO   (United States)

more..

Author keywords

Hematopoietic stem cell transplant; Immunocompromised; IVIG; Lung transplant; Respiratory syncytial virus; Ribavirin; RSV

Indexed keywords

IMMUNOGLOBULIN; RIBAVIRIN; ANTIVIRUS AGENT;

ADULT; ARTICLE; CORONAVIRIDAE INFECTION; COST BENEFIT ANALYSIS; GRAFT VERSUS HOST REACTION; HEALTH SURVEY; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOCOMPROMIZED PATIENT; LOWER RESPIRATORY TRACT INFECTION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; METAPNEUMOVIRUS; METAPNEUMOVIRUS INFECTION; MULTIPLEX POLYMERASE CHAIN REACTION; PARAINFLUENZA VIRUS INFECTION; PATIENT SAFETY; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RESPIRATORY VIRUS; UPPER RESPIRATORY TRACT INFECTION; VIRAL RESPIRATORY TRACT INFECTION; ADVERSE EFFECTS; IMMUNOCOMPROMISED PATIENT; INFORMATION PROCESSING; ORAL DRUG ADMINISTRATION; ORGAN TRANSPLANTATION; RESPIRATORY CARE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS;

ADMINISTRATION, ORAL; ANTIVIRAL AGENTS; DATA COLLECTION; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOGLOBULINS, INTRAVENOUS; ORGAN TRANSPLANTATION; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; RESPIRATORY THERAPY; RIBAVIRIN;

EID: 84962463234     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12510     Document Type: Article

References (21)

1. Kim YJ, Guthrie KA, Waghmare A, et al. Respiratory syncytial virus in hematopoietic cell transplant recipients: factors determining progression to lower respiratory tract disease. J Infect Dis 2014; 209 (8): 1195-1204.
2. Waghmare A, Campbell AP, Xie H, et al. Respiratory syncytial virus lower respiratory disease in hematopoietic cell transplant recipients: viral RNA detection in blood, antiviral treatment, and clinical outcomes. Clin Infect Dis 2013; 57 (12): 1731-1741.
3. Shah DP, Ghantoji SS, Mulanovich VE, Ariza-Heredia EJ, Chemaly RF. Management of respiratory viral infections in hematopoietic cell transplant recipients. Am J Blood Res 2012; 2 (4): 203-218.
4. Li L, Avery R, Budev M, Mossad S, Danziger-Isakov L. Oral versus inhaled ribavirin therapy for respiratory syncytial virus infection after lung transplantation. J Heart Lung Transplant 2012; 31 (8): 839-844.
5. Kumar D, Erdman D, Keshavjee S, et al. Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant. Am J Transplant 2005; 5 (8): 2031-2036.
6. Chemaly RF, Shah DP, Boeckh MJ. Management of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignancies. Clin Infect Dis 2014; 59 (Suppl 5): S344-S351.
7. Hemming VG, Prince GA, Groothuis JR, Siber GR. Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections. Clin Microbiol Rev 1995; 8 (1): 22-33.
8. Shah JN, Chemaly RF. Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. Blood 2011; 117 (10): 2755-2763.
9. Shah DP, Ghantoji SS, Shah JN, et al. Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections. J Antimicrob Chemother 2013; 68 (8): 1872-1880.
10. Khanna N, Widmer AF, Decker M, et al. Respiratory syncytial virus infection in patients with hematological diseases: single-center study and review of the literature. Clin Infect Dis 2008; 46 (3): 402-412.
11. Marcelin JR, Wilson JW. Razonable RR; Mayo Clinic Hematology/Oncology and Transplant Infectious Diseases Services. Oral ribavirin therapy for respiratory syncytial virus infections in moderately to severely immunocompromised patients. Transpl Infect Dis 2014; 16 (2): 242-250.
12. Gueller S, Duenzinger U, Wolf T, et al. Successful systemic high-dose ribavirin treatment of respiratory syncytial virus-induced infections occurring pre-engraftment in allogeneic hematopoietic stem cell transplant recipients. Transpl Infect Dis 2013; 15 (4): 435-440.
13. Pelaez A, Lyon GM, Force SD, et al. Efficacy of oral ribavirin in lung transplant patients with respiratory syncytial virus lower respiratory tract infection. J Heart Lung Transplant 2009; 28 (1): 67-71.
14. Chemaly RF, Torres HA, Munsell MF, et al. An adaptive randomized trial of an intermittent dosing schedule of aerosolized ribavirin in patients with cancer and respiratory syncytial virus infection. J Infect Dis 2012; 206 (9): 1367-1371.
15. Cortez K, Murphy BR, Almeida KN, et al. Immune-globulin prophylaxis of respiratory syncytial virus infection in patients undergoing stem-cell transplantation. J Infect Dis 2002; 186 (6): 834-838.
16. de Fontbrune FS, Robin M, Porcher R, et al. Palivizumab treatment of respiratory syncytial virus infection after allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2007; 45 (8): 1019-1024.
17. Liu V, Dhillon GS, Weill D. A multi-drug regimen for respiratory syncytial virus and parainfluenza virus infections in adult lung and heart-lung transplant recipients. Transpl Infect Dis 2010; 12 (1): 38-44.
18. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011; 52 (4): e56-e93.
19. Zamora MR, Budev M, Rolfe M, et al. RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. Am J Respir Crit Care Med 2011; 183 (4): 531-538.
20. DeVincenzo JP, Whitley RJ, Mackman RL, et al. Oral GS-5806 activity in a respiratory syncytial virus challenge study. N Engl J Med 2014; 371 (8): 711-722.
21. DeVincenzo J, Lambkin-Williams R, Wilkinson T, et al. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci USA 2010; 107 (19): 8800-8805.